1. Introduction {#s1}
===============

Preclinical scientific research has been increasingly criticized for a lack of reproducibility. Recent publications^[@R3],[@R7],[@R14],[@R22],[@R25],[@R32]^ have demonstrated an alarmingly low level of reproducibility in biomedical research fields. In a survey of 1576 scientists,^[@R1]^ more than 70% could not reproduce published results and more than 50% could not reproduce findings from their own experiments, leading to discussion of a "reproducibility crisis." Data from psychology^[@R22]^ and cancer biology^[@R2]^ research showed only 40% and 11% of study results were reproducible, respectively.

Preclinical studies are often published based on a single laboratory\'s results and typically have implications for mechanistic understanding and progression of molecules towards human trials. Factors that can influence validity of conclusions include, but are not limited to, evaluation methods in a specific laboratory involving randomization, investigator blinding, inclusion of all data and statistical power. Other sources of variability include the strain, sex, source and handling procedures of animals, as well as the quality of the molecule (eg, pharmacokinetic profile and relevant tissue exposure) being evaluated. Inclusion of rigorous quality controls is necessary to help facilitate data replication. Moreover, even with highly standardized conditions, natural biological variability can be overlooked, resulting in false interpretation of data outcomes and/or failure of replication in other laboratory settings. Voelkl et al.^[@R33]^ did a meta-analysis showing that results from multilaboratory (as few as 2-4 laboratories) studies produced ∼30% to 40% increase of accurate prediction of the true effect size in animal models of stroke, myocardial infarction, and breast cancer. The National Institutes of Health has emphasized that key preclinical studies may first need to be validated independently especially when a potentially costly human clinical trial is proposed based on animal-model results.^[@R5]^ Here, we attempted to replicate a recent single study, suggesting the efficacy of Meteorin in treating nerve injury--induced neuropathic pain.

Meteorin is a member of a newly described family of secreted proteins that is highly expressed in the mammalian brain throughout development and at lower levels in the postnatal brain.^[@R12],[@R21]^ Meteorin promotes gliogenesis and, similar to a number of other neurotrophic factors, enhances neurite outgrowth of nociceptive sensory neurons in dorsal root ganglia (DRG) isolated from rodents.^[@R21],[@R34]^ Based on these latter findings, Jorgensen et al.^[@R13]^ proceeded to assess the efficacy of repeated systemic injections of Meteorin in 2 distinct rat models of peripheral nerve injury. Meteorin reversed mechanical and cold allodynia in rats with photochemical sciatic nerve injury, and mechanical allodynia and heat hyperalgesia in chronic constriction injury (CCI) rats. In both models, the maximum efficacy of Meteorin was reached slowly and outlasted the elimination of the compound from the blood (\<24 hours after a single subcutaneous \[s.c.\] injection) by weeks,^[@R13]^ suggesting potential "disease-modification." If true, this would differentiate Meteorin from currently available therapeutics.

We performed a replication study under strict experimental conditions of randomization and blinding aimed at confirming Meteorin efficacy in the rat CCI model. Our findings have reproduced key data sets in a different laboratory setting.

2. Methods {#s2}
==========

2.1. Animals {#s2-1}
------------

Pathogen-free, adult male Sprague-Dawley rats (150-200 g; Envigo, Indianapolis, IN) were housed in temperature (23 ± 3°C), light (20-40 lux, 12-hour light/12-hour dark cycle; lights on 07:00-19:00), and humidity (30%-70%) controlled rooms with standard rodent chow (Teklad 2018 Global Rodent Diet; Envigo) and tap water available ad libitum. Clear individually ventilated rat cages were used to house 3 rats per cage with the same cagemates before and after CCI surgery. Standard cage beddings (Corncob Bedding from Teklad; Envigo) were used. All animals were allowed to acclimate to the facilities for 3 to 5 days before being subject to behavioral tests. Diamond Twist nesting materials and PVC tubes were provided as environmental enrichment. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Arizona. All procedures were conducted in accordance with the Guide for Care and Use of Laboratory Animals published by the National Institutes of Health and the ethical guidelines of the International Association for the Study of Pain. Animals were randomly assigned to treatment or control groups for the behavioral experiments.

2.2. Study design {#s2-2}
-----------------

The experiments were designed to follow the methods of Jorgensen et al. as closely as possible (see Fig. [1](#F1){ref-type="fig"} for study design). Chronic constriction injury was chosen as the experimental model to produce chronic neuropathic pain. Mechanical hyperalgesia and cold allodynia were selected as outcome measures. Mechanical and cold thresholds were assessed before CCI surgery and at days 10, 12, 14, 17, 19, 21, 26, 32, 39, and 41 after CCI. Meteorin (0.5 and 1.8 mg/kg, s.c.) or vehicle was administered at days 10, 12, 14, 17, and 19 after behavioral testing. At the end of the experiment and Meteorin unblinding, the vehicle-treated animals were reused to assess the efficacy of the reference compound, gabapentin (100 mg/kg, orally), against the same 2 output measures at day 42 after CCI. These rats were then crossed over to receive the corresponding treatment (switching between gabapentin and water treatment) at day 45 after a 3-day washout period. The grouping information for gabapentin and water was concealed from the experimenter until after completion of the entire study.

![Schematic illustration of the study design. BL, naive baseline (day -1); CCI, chronic constriction injury; s.c., subcutaneous.](jop-160-1847-g001){#F1}

2.3. Blinding {#s2-3}
-------------

All behavioral experiments were performed by an experimenter blinded to treatments. The blinding of the data collection was achieved by having 3 separate people prepare and code the solutions as follows: Experimenter 1 assigned the animals into different groups, experimenter 2 performed the drug treatments and evaluated the behavioral outcomes, and experimenter 3 unblinded the results and analyzed and plotted the data.

2.4. Chronic constriction injury {#s2-4}
--------------------------------

Chronic constriction injury surgeries were performed according to Bennett and Xie.^[@R4]^ Briefly, rats were anesthetized with 5% isofluorane in air at 1 L/min and maintained with 2.5% isofluorane. The sciatic nerve of the left hindlimb was exposed at the midthigh level. Four loose ligatures using 4-0 chromic gut suture were placed around the exposed sciatic nerve with about 2 mm between ligatures. Sham-operated animals underwent the same procedure but without the ligatures to the sciatic nerve. No antibiotics or preoperative or postoperative analgesics were administered in accordance with approved IACUC procedures. Cold allodynia and mechanical hyperalgesia were assessed before and at days 10, 12, 14, 17, 19, 21, 26, 32, 39, and 42 after the surgery.

2.5. Assessment of cold allodynia and mechanical hyperalgesia {#s2-5}
-------------------------------------------------------------

Cold allodynia was evaluated by placing each rat individually in an enclosed Plexiglas chamber (22 cm L × 11 cm W × 20 cm H) on a metal plate of the same dimension maintained at 4°C. The frequency and accumulated duration of guarding of the injured hindpaw were measured for 2 minutes. The rats were returned to their home cages afterwards. After 0.5 to 1 hour, the assessment of mechanical hyperalgesia was performed using a Randall--Selitto apparatus (Ugo-Basile algesimeter; Stoelting, Chicago, IL).^[@R26]^ It consisted of measuring the withdrawal threshold of the hindpaw both ipsilateral and contralateral to the site of nerve injury in response to continuously increased pressure. A sharp withdrawal of the hindpaw or vocalization was taken as the endpoint. The paw withdrawal thresholds for each hindpaw were assessed 2 times consecutively, alternating between the 2 sides starting from the contralateral side. A cutoff at 500 g was used to avoid tissue injury. Mechanical thresholds were expressed as the average ipsilateral and contralateral paw withdrawal thresholds. Percent antihyperalgesia (%Antihyperalgesia) was calculated as: (after dose − before dose)/(baseline − before dose) × 100. One animal was removed from the experiment because of lack of mechanical hyperalgesia at day 10 after CCI before any treatment. All other animals were kept in the experiment, and no data with Meteorin treatment were excluded from analysis.

2.6. Measurement of Meteorin concentration in the plasma and brain {#s2-6}
------------------------------------------------------------------

Separate cohorts of naive rats were treated with Meteorin (1.8 mg/kg, s.c.) acutely at day 1 or repeatedly at days 1, 3, 5, 8, and 10 (n = 3/group). Blood (∼2 mL) was collected by cardiac puncture under isoflurane anesthesia at 4 hours after the last dose and immediately put into K3-EDTA--coated tubes. The samples were centrifuged at 3300*g* for 10 minutes at 4°C. Plasma (approximate 1.2 mL) was removed and then transferred to Micronic tubes and stored at −80°C. After blood collection, the animals were sacrificed through isoflurane overdose, and both brain hemispheres and the cerebellum (which was split into 2 halves) were harvested and the tissue weighed and stored at −80°C. Thereafter, one brain hemisphere and one half of the cerebellum were homogenized in ×10 radioimmunoprecipitation assay lysis buffer (Millipore, Catalogue no. 20-188), with added protease inhibitor cocktail (Sigma P8340; Sigma, St. Louis, MO) at 100 µL per 10 mL of lysis buffer. The mixture was left on a shaker for 45 minutes at 4°C and then centrifuged at 13,000*g* for 20 minutes at room temperature and the supernatant removed. The concentrations of Meteorin in plasma and brain samples were analyzed in duplicates according to the manufacturer instructions using a commercially available enzyme-linked immunospecific assay and reagent kit (Catalogue no.\'s DY3475 and DY008) purchased from R&D Systems, Minneapolis, MN.

2.7. Drugs {#s2-7}
----------

Recombinant Meteorin (Catalogue no. 3475-MN) was purchased from R&D Systems Inc. Briefly, the sequence encoding mouse Meteorin (Q8C1Q4) was cloned and expressed in an NS0 mouse myeloma cell line. The recombinant mouse Meteorin was purified from the conditioned medium by ion exchange, hydrophobic interaction, and size exclusion chromatography. The buffer was exchanged into phosphate buffered saline (PBS) and the protein solution stored at −80°C. The purity of the preparation was 95% determined by densitometry scan. The bioactivity of Meteorin was confirmed by measuring its ability to enhance neurite outgrowth of E16 to E18 rat embryonic cortical neurons. Accordingly, Meteorin administered in the range of 60 to 300 ng/3 μL was shown to enhance neurite outgrowth (<https://www.rndsystems.com/products/recombinant-mouse-meteorin-protein_3475-mn#product-datasheets>). For pharmacology testing, Meteorin was dissolved in Dulbeccos PBS freshly each day at room temperature and injected s.c. at 5 mL/kg. The s.c. injections were made at the nape of the neck while the skin was gently pulled up. Gabapentin (Catalogue no. PHR1049; Sigma) was dissolved in deionized water and dosed orally at 2 mL/kg.

2.8. Data analysis {#s2-8}
------------------

The statistical significance of differences between mean values was determined by either parametric or nonparametric analysis of variance followed by post hoc comparisons (the Dunnett or Tukey test) and/or the unpaired *t* test using GraphPad Prism 7. Differences were considered to be significant if *P* \< 0.05. A specific power analysis was not used for estimation of group sizes in the current study. Rather, the group size was set to 8 based on empirical experience in our laboratory; similar group sizes (n = 8 for photochemical assay and n = 6 for CCI assay) were reported by Jorgensen et al. (2012). One rat was removed from the study because it failed to develop mechanical hyperalgesia at day 10 after CCI before administration of any treatment.

3. Results {#s3}
==========

3.1. Meteorin reversed mechanical hyperalgesia after chronic constriction injury {#s3-1}
--------------------------------------------------------------------------------

Two doses of recombinant mouse Meteorin (0.5 and 1.8 mg/kg, s.c.) or vehicle were given at days 10, 12, 14, 17, and 19 after CCI. Paw withdrawal threshold to mechanical pressure was assessed using the Randall--Selitto apparatus before the surgery and then on the same days of drug treatment after surgery before dosing. Behavior was subsequently monitored at days 21, 26, 32, 39, and 42 after CCI (Fig. [2](#F2){ref-type="fig"}).

![The effect of Meteorin on mechanical hyperalgesia induced by CCI in male SD rats. Hindpaw withdrawal thresholds over time were assessed before and after CCI surgery at days 10, 12, 14, 17, 19, 21, 26, 32, 39, and 42 using a Randall--Selitto apparatus. Meteorin (0.5, 1.8 mg/kg, s.c.) or vehicle (Dulbecco\'s PBS, 5 mL/kg, s.c.) was given at days 10, 12, 14, 17, and 19 after CCI immediately after hindpaw mechanical responses had been assessed. (A) Left (ipsilateral to the nerve injury) hindpaw withdrawal thresholds. (B) %Antihyperalgesia of the left hindpaw. (C) Withdrawal threshold of the right hindpaw. (D) Chronological changes of body weights. Chronic constriction injury induced robust mechanical hyperalgesia compared with presurgery (naive) baseline (\**P* \< 0.05). Meteorin reversed mechanical hyperalgesia compared with predose baseline (\#*P* \< 0.05) or vehicle control (\^*P* \< 0.05) at the same time point. A small, yet significant, change in the contralateral paw withdrawal threshold was observed in the vehicle-treated group at days 17 and 19 after CCI. This change was not observed in the high-dose (1.8 mg/kg) Meteorin-treated group. The body weights were comparable among all treatment groups. The repeated-measure two-way ANOVA post hoc Tukey multiple comparison test was used for statistical analysis. N = 7 to 8/group. ANOVA, analysis of variance; BL, naive baseline (day -1); CCI, chronic constriction injury; s.c., subcutaneously; SD, Sprague-Dawley.](jop-160-1847-g002){#F2}

Nerve injury produced a long-lasting reduction of the ipsilateral hindpaw mechanical threshold compared with the naive baseline (*P* \< 0.0001) in CCI rats. The mean withdrawal threshold of the ipsilateral hindpaw was significantly reduced from a baseline of 194.75 ± 4.54 to 146.25 ± 4.30 g (day 10) after CCI and remained lower in the CCI vehicle-treated group at all the time points measured (Figs. [2](#F2){ref-type="fig"}A and B. \**P* \< 0.0001 compared with baseline in the same group), while repeated s.c. administration of Meteorin reversed mechanical hyperalgesia in an apparent dose-related manner as the higher dose showed better efficacy than the lower dose. We did not construct a dose--response curve in these studies. The reduction of the mechanical hyperalgesia was significant at days 12, 14, 17, 19, 21, 26, 32, 39, and 42 compared with predose baseline (day 10 after CCI) and at days 14, 17, 19, 21, 26, and 32 compared with the vehicle control at the same time point after the highest dose (1.8 mg/kg, s.c.) of Meteorin tested (*P* \< 0.0001). The peak effect (∼100% antihyperalgesia) was reached at day 17 after 3 doses, and the antihyperalgesic effect was significant for more than 2 weeks after the termination of the treatment. The antihyperalgesic effect diminished at day 39 after CCI (20 days after the last dose of Meteorin). The lower dose (0.5 mg/kg, s.c.) of Meteorin produced ∼60% reduction of mechanical hyperalgesia at days 14, 17, 21, 26, 32, and 39 after CCI compared with predose baseline (*P* \< 0.01), and the antihyperalgesic effect was significantly different from vehicle treatment at days 14 and 17 (*P* \< 0.05).

No significant change of mechanical threshold was observed at day 10 after CCI in the contralateral hindpaw (Fig. [2](#F2){ref-type="fig"}C). After the treatment, there was a small, but significant reduction of the paw withdrawal threshold at days 17 and 19 after CCI in the vehicle-treated group and at day 17 after low-dose Meteorin treatment compared with predose baseline at day 10, respectively (*P* \< 0.05). However, no significant change was observed after high-dose Meteorin treatment (*P* \> 0.05). No significant differences were detected between the treatment groups (*P* \> 0.05), and no analgesic effects were observed because no treatment raised the paw withdrawal threshold above the presurgery baseline.

No observable side effects were noted during the entire study from any treatment groups. The animals\' coat was smooth. Their locomotion and social behaviors appeared normal. No audible vocalization when handled. The body weight of the animals did not differ among groups during the course of the study (Fig. [2](#F2){ref-type="fig"}D).

3.2. Meteorin reversed cold allodynia after chronic constriction injury {#s3-2}
-----------------------------------------------------------------------

The same study design was adopted to determine the guarding responses to noxious cold stimuli after CCI (Fig. [3](#F3){ref-type="fig"}). The frequency and accumulated duration of guarding were assessed using a cold metal plate set at 4°C before the surgery, and responses were assessed before the assessment of mechanical hyperalgesia on the same postsurgical days. By day 10 after CCI, cold allodynia developed in the ipsilateral paw of CCI rats manifested as increases of total number of guarding frequency and accumulated guarding duration in 2 minutes to noxious cold stimuli on the 4°C cold plate (Fig. [3](#F3){ref-type="fig"}). The cold response diminished over time in the vehicle-treated group, suggesting resolution of cold allodynia or adaptation to the testing apparatus. Meteorin at the dose of 1.8 mg/kg shortened the accumulated guarding duration at days 12, 14, 17, 19, 21, 26, and 42 (Figs. [3](#F3){ref-type="fig"}A and B) and decreased the guarding frequency at day 19 (Figs. [3](#F3){ref-type="fig"}C and D) (*P* \< 0.05 compared with day 10 after CCI before the drug treatment). No significant effects were observed after 0.5 mg/kg Meteorin treatment.

![The effect of systemic Meteorin on cold allodynia induced by CCI in male SD rats. The response of the ipsilateral (left) hindpaw in 2 minutes to a noxious cold stimulus on a 4°C cold plate was assessed before and after CCI surgery at days 10, 12, 14, 17, 19, 21, 26, 32, 39, and 42. Meteorin (0.5, 1.8 mg/kg, s.c.) or vehicle (Dulbecco\'s PBS, 5 mL/kg, s.c.) was given at days 10, 12, 14, 17, and 19 after CCI. (A) Accumulated duration of guarding. (B) Bar graph illustrating the change of guarding duration at early and peak efficacy time points. (C) Guarding frequency. (D) Bar graph illustrating the change of guarding frequency at early and peak efficacy time points. Chronic constriction injury induced significant cold allodynia as assessed using both measures (\**P* \< 0.05 compared with presurgery \[naive\] baseline). This effect diminished over time with repeated measurement. High-dose Meteorin (1.8 mg/kg) significantly reduced the guarding duration at days 12, 14, 17, 19, 21, 26, and 42 and guarding frequency at day 19 after CCI compared with predose baseline (\#*P* \< 0.05). The data were analyzed using the repeated-measure two-way ANOVA with the Tukey multiple comparison test (A) and the Friedman test with the Dunn multiple comparison test (B). N = 8/group. ANOVA, analysis of variance; CCI, chronic constriction injury; s.c., subcutaneously; SD, Sprague-Dawley.](jop-160-1847-g003){#F3}

3.3. Gabapentin reversed mechanical hyperalgesia and cold allodynia of the ipsilateral paw {#s3-3}
------------------------------------------------------------------------------------------

Gabapentin is a first-line therapy for neuropathic pain and was used here as a standard reference comparator. Therefore, oral gabapentin (100 mg/kg) was used as a positive control at the end of the studies. Rats previously treated with vehicle for Meteorin were tested at days 42 to 45 after CCI using a crossover design, so that rats that received gabapentin first were given vehicle after 3 days and vice versa allowing for assessment of the antihyperalgesic effects of gabapentin. Two hours after treatment, gabapentin significantly raised the withdrawal threshold of the ipsilateral (left) hindpaw in CCI rats compared with predose (day 10) baseline or vehicle control (*P* \< 0.0001, Fig. [4](#F4){ref-type="fig"}A). %Antihyperalgesia of the ipsilateral hindpaw showed 100% reversal of the mechanical hyperalgesia by gabapentin (Fig. [4](#F4){ref-type="fig"}B). No change was observed to the contralateral (right) hindpaw by gabapentin (*P* \> 0.05, data not shown). Similarly, gabapentin significantly decreased cold allodynia induced by CCI. At 2 hours after dose, the guarding duration (Fig. [4](#F4){ref-type="fig"}C) and frequency (Fig. [4](#F4){ref-type="fig"}D) were significantly lower than that of vehicle control (*P* \< 0.05).

![Antihyperalgesic effects of gabapentin on mechanical hyperalgesia in CCI rats. At day 45 after CCI injury, the ipsilateral paw withdrawal threshold (A and B) to a noxious mechanical stimulus, and guarding duration (C) and frequency (D) to a noxious cold stimulus were measured before and 2 hours after gabapentin (100 mg/kg, p.o.) or vehicle (DiH~2~O, 2 mL/kg, p.o.) administration. Chronic constriction injury induced significant mechanical hyperalgesia (A and B) and cold allodynia (C and D) for both measures (\**P* \< 0.05 compared with presurgery \[naive\] baseline). Gabapentin significantly reversed CCI-induced mechanical hyperalgesia in the ipsilateral hindpaw compared with predose baseline (\#*P* \< 0.05) or vehicle control (\^*P* \< 0.05). The data were analyzed using the repeated-measure two-way ANOVA post hoc Tukey multiple comparison test (A, C, and D) or unpaired *t* test (B). N = 8/group. ANOVA, analysis of variance; BL, naive baseline (day -1); CCI, chronic constriction injury (D45 after surgery); p.o., orally.](jop-160-1847-g004){#F4}

3.4. Levels of Meteorin in rat plasma and brain after acute and repeated systemic administration {#s3-4}
------------------------------------------------------------------------------------------------

Separate cohorts of naive rats were dosed with acute (at day 1) or repeated Meteorin (at days 1, 3, 5, 8, and 10), and their blood and brain samples were harvested for the assessment of plasma and brain exposure (Fig. [5](#F5){ref-type="fig"}). Accordingly, 4 hours after acute injection at day 1, the plasma concentration of Meteorin was 416.7 ± 24.5 ng/mL, and 4 hours after the last injection after repeated administration at day 10, the plasma concentration was 713 ± 46.8 ng/mL. By contrast, in the same rats, only very low levels of mouse Meteorin were detected in the brain parenchyma after acute (0.97 ± 0.04 ng/mL/g brain tissue) and repeated (1.06 ± 0.16 ng/mL/g brain tissue) Meteorin administration.

![Meteorin concentrations in the rat plasma and brain. Plasma and brain samples were obtained from naive rats at 4 hours after the acute injection or 4 hours after the last injection of Meteorin (1.8 mg/kg, s.c.) after 5 repeated administration at days 1, 3, 5, 8, and 10. Data are presented as mean ± SEM. The concentrations of Meteorin were determined by enzyme-linked immunospecific assay. \**P* \< 0.05 compared with acute administration in plasma. The unpaired *t* test was used (N = 3/group).](jop-160-1847-g005){#F5}

4. Discussion {#s4}
=============

The data from this study have replicated key features and conclusions supporting Meteorin efficacy in neuropathic pain as originally reported by Jorgensen et al.^[@R13]^ These include reversal of mechanical and cold hypersensitivity, time to onset of analgesic efficacy, and prolonged duration of action upon cessation of Meteorin treatment. Importantly, a strict blinding regimen was used to eliminate potential experimenter bias that could interfere with interpretation of the results, and the experiments were performed using well-characterized biological material.

We adopted the overall study design used in the original report of Jorgensen et al. (Fig. [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Accordingly, male Sprague-Dawley rats were subjected to CCI and, upon developing appropriate neuropathic hypersensitivity, were then administered recombinant mouse Meteorin at the same time point (day 10) after injury. We ensured that Meteorin was sourced from the same vendor, wherein different protein batches were provided as a unit of mass per vial (25 μg) with a specific activity range estimated using the same neurite extension bioassay. Thereafter, identical handling (eg, avoidance of freeze-thawing, etc.), formulation, and dosing of Meteorin were followed, a process that was facilitated by one of the original authors of the Jorgensen article in the current study (G.M.). Thus, we are confident that the quality and functional bioactivity of Meteorin were as similar as possible in the 2 independent studies.

###### 

Comparison of key features of rat CCI study design and methods with Jorgensen et al.

![](jop-160-1847-g006)

Nevertheless, a number of protocol deviations did occur as highlighted in Table [1](#T1){ref-type="table"}. We obtained our rats from Envigo as this is the provider we standardly use for experimental research. Sprague-Dawley rats are an outbred strain and have been reported to develop different levels of neuropathic hypersensitivity and sensitivity to analgesics after CCI depending on the vendor from which they are sourced.^[@R16]^ However, we do not believe this to have been an issue per se, since if the effect size of Meteorin could not have overcome the potential difference among Sprague-Dawley rats from different vendors, the translational value of this study would have been highly diminished. Another key difference is that we measured mechanical and thermal hindpaw thresholds using distinct reflex sensory testing methods. Numerous reports have described the presence of mechanical allodynia after CCI injury, albeit a wide range of effect magnitude has been reported.^[@R6],[@R8],[@R15],[@R19]^ However, previous studies in our laboratory have not demonstrated a consistently reproducible tactile allodynia in the CCI model. Moreover, data from many previously reported studies may reflect the presence of mechanical hyperalgesia rather than allodynia per se, given that the upper range of von Frey filaments used evoked a reflex nociceptive response at baseline before injury which by definition excludes allodynia.^[@R17],[@R20],[@R27]--[@R31],[@R36]^ Again, pragmatic reasons informed our decision to assess the effect of Meteorin on cold allodynia in CCI rats compared with the thermal hyperalgesia reported by Jorgensen et al. (2012);^[@R13]^ note that Meteorin was shown to attenuate cold hypersensitivity in a rat model of photochemical-induced ischaemic neuropathic pain by the same authors. Although multiple studies report the presence of heat hyperalgesia in the CCI model,^[@R35]--[@R37]^ we have previously observed that the injured hindpaw displays a curved plantar surface (ie, "cupping") that does not easily allow for focused application of the radiant heat stimulus to the injured paw.

Despite the differences in the sensory output measures evaluated, our results remain highly consistent with those reported by Jorgensen et al. Thus, we observed that Meteorin produces an inhibition of neuropathic hypersensitivity in CCI rats that reached a peak effect of almost 100% reversal to baseline after the third injection of Meteorin. In addition, we also observed similar efficacy against mechanical and cold endpoints with gabapentin at study end, the inclusion of which helps align the sensitivity of our assay testing conditions with other laboratories worldwide. However, although Meteorin efficacy was originally described as being relatively slow in onset, only becoming clearly apparent after 2 injections, statistical analysis of the current data with an all pairwise test (which allowed for comparison with the corresponding predose baseline threshold value) revealed that the high dose of Meteorin alleviated mechanical hypersensitivity already after the first injection. We do not believe that this finding can be attributed to different exposure levels of Meteorin between the 2 studies because pharmacokinetic analysis of blood at 4 hours after either acute or 5 repeated s.c. injections of Meteorin confirmed that plasma levels in the current study aligned with those reported previously.^[@R13]^ While Meteorin seemed to accumulate in plasma after repeated injections, plasma concentrations in the ng/mL range are cleared within 24 hours^[@R13]^ and so are highly unlikely to account for the profound efficacy obtained with Meteorin that persisted \>2 weeks after termination of the treatment in each study. Considered together, our data not only provide confirmation of Meteorin efficacy in this preclinical model, but also increase our confidence in the efficacy of Meteorin in neuropathic pain because its effects are not limited to specific sensory modalities or observable under specific laboratory conditions.

It is noteworthy that brain levels of Meteorin were about 500-fold lower than in plasma, a finding consistent with the size and structure of Meteorin. Moreover, the measured brain concentrations were in the order of 20-fold lower than that required to mediate neurite extension in cultured DRG explants (EC~50~ = 20 ng/mL).^[@R21]^ Taken together, this suggests that systemically administered Meteorin most likely has a peripheral site of action, albeit it does not readily inform on potential underlying mechanism(s) of action. Although the receptor for Meteorin remains to be identified, potential insights can be gleamed from other studies showing that it promotes endothelial maturation,^[@R23]^ angiogenesis,^[@R23]^ and glial cell differentiation.^[@R21],[@R34]^ Peripheral nerve injury can induce morphological and plasticity changes in glial cells within DRG which in turn have been linked to spinal cord microglial activation and subsequent central sensitization.^[@R9],[@R10],[@R18]^ Meteorin on the other hand induces axonal extension of peripheral sensory neurons in DRG^[@R11]^ and trigeminal cell cultures through a process that also seems to involve activation of neighbouring satellite glia possibly promoting secondary effects that are either directly neuritogenic, act in concert with Meteorin, or increase the responsiveness of injured neurones to other trophic factors.^[@R21]^ It is reasonable to speculate that these processes might be relevant in explaining the slow onset and long-lasting effects of Meteorin to alleviate tactile and cold hypersensitivity after CCI but such conclusions require future investigation.

We also measured mechanical thresholds for the uninjured hindpaw of CCI rats in our experiment. Typically, this measure is not reported in experimental studies involving neuropathic pain models. We noted that the mechanical pressure threshold for the uninjured hindpaw showed a small, yet significant, reduction at days 17 and 19 after CCI that was reversed by Meteorin. Whether this small decrease of mechanical threshold is an experimental artifact or a consequence of central sensitization, possibly reflecting mirror pain, remains to be further elucidated. Significant changes of contralateral hindpaw mechanical thresholds have been reported previously in a sciatic nerve CCI induced by a cuff injury in rats.^[@R24]^ In our study, the magnitude of the paw pressure threshold reduction in the contralateral hindpaw was small compared with that of the ipsilateral hindpaw. Whether this statistically significant reduction is biologically relevant remains to be explored. Nonetheless, it highlights the value of assessing thresholds for both the ipsilateral and contralateral hindpaw in such models.

In conclusion, our study has replicated key findings of a single previous preclinical study supporting the potential efficacy of Meteorin in the treatment of neuropathic pain. The consistency of results, despite inherent protocol deviations, suggests that the biological effects are robust, with further studies required to uncover the underlying mechanism(s) for the observed effects. The replication of Meteorin efficacy across independent laboratories also provides support for future development of this molecule as a potential therapy.
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